Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3

Conditions

Ovarian Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 291Gemcitabine 254Carboplatin 253Cisplatin 250Radiotherapy 219Cyclophosphamide 218Irinotecan 184pembrolizumab 180Docetaxel 174Bevacizumab 166Capecitabine 148Nivolumab 141Fluorouracil 132Dexamethasone 125Bortezomib 123Oxaliplatin 115Cytarabine 113Erlotinib Hydrochloride 112Temozolomide 110Sorafenib 110Doxorubicin 106Rituximab 105Leucovorin 105Etoposide 105Filgrastim 99Everolimus 97Lenalidomide 95Ipilimumab 90Pemetrexed 89fludarabine phosphate 84

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Completed × GEN-1 × Clear all
NCT02480374 2024-10-02

Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer

Imunon

Phase 1 Completed
18 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT01489371 2019-03-12

EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

GOG Foundation

Phase 1 Completed
16 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00473954 2013-03-26

Safety and Efficacy of EGEN-001 Combined With Carboplatin and Docetaxel in Recurrent, Platinum-Sensitive, Ovarian Cancer

EGEN, Inc.

Phase 1 Completed
13 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡